Organisation paid for research Program year 2024 Source: CMS Open Payments

Washingtonuniversity

Neither a doctor nor a teaching hospital

Research payments

$106,780

26 payments

Through program year 2024, Washingtonuniversity is reported as receiving $106,780 in research payments, across 26 payments.

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$7,520	4
2022	Research	$32,020	5
2021	Research	$8,110	4
2020	Research	$58,977	12
2019	Research	$153	1

Breakdown

Who paid Research payments · program years 2019–2024

Agios Pharmaceuticals, Inc. $106,780 26 payments

Studies the money was for Research payments · program years 2019–2024

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Vorasidenib in Subjects with Recurrent, Non-enhancing, Low-grade Glioma with an IDH1 or IDH2 Mutation $35,620 6 payments
A Phase 2a/2b, Multicenter, Proof of Concept, Efficacy, and Safety Study of AG 946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes $32,020 5 payments
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of AG-120 in Previously-treated Subjects with Nonresectable or Metastatic Cholangiocarcinoma with an IDH1 Mutation $19,197 6 payments
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation $12,270 4 payments
A Study of AG-946 in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) $7,520 4 payments
Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With Idh1 Mutations Claridhy $153 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.